樂普生物-B(02157.HK):中國證監會向公司發出有關H股全流通申請的備案通知書
格隆匯5月28日丨樂普生物-B(02157.HK)公吿,公司已於近期向中國證券監督管理委員會("中國證監會")提交有關公司進行H股全流通的備案。公司已代表公司若干股東向中國證監會提出備案申請,將其持有的公司合計54,268,364股境內未上市股份轉換為公司H股並在聯交所上市("轉換及上市")。
公司欣然宣佈,於2025年5月26日,中國證監會已向公司發出轉換及上市備案通知書("備案通知書")。根據備案通知書,有關轉換及上市的中國證監會備案已完成,若公司自備案通知書出具日起12個月內未完成轉換及上市,擬繼續推進的,應當更新備案材料。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.